Combating infective agents with Probiotics:  Probiotics-based adjuvant therapy for viral and bacterial infections: Probiotic Bacillus subtilis B10 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene, 24/October/2018, 10.31 pm

Taming microbial infections with anti-tapeworm drugs:  Niclosamide (trade name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene 22/October/2018, 11.59 pm
October 22, 2018
Anti-hypertensive drug Amlodipine for an enhanced, extended, and healthy lifespan: Amlodipine (trade name: Norvasc) increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 24/October/2018, 10.46 pm
October 24, 2018
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combating infective agents with Probiotics:  Probiotics-based adjuvant therapy for viral and bacterial infections: Probiotic Bacillus subtilis B10 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene


What is known?

Prof. Stephen Elledge research team has shown that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that Probiotic Bacillus subtilis B10, by decreasing the expression of its target genes, it may increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2, and antimicrobial peptides. Thereby, it may: (1) inhibit the replication of  Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing “Probiotic Bacillus subtilis B10, either alone or in combination with other drugs,” may be used to prevent/treat infections caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses (Figure 2).

Figure 1. Mechanistic insight into how Probiotic Bacillus subtilis B10 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial, Sindbis, and SFV viruses production. Probiotic Bacillus subtilis B10 functions as a broad-spectrum anti-infective agent through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, & Mx2

Figure 2. Probiotic Bacillus subtilis B10 may function as a broad-spectrum anti-infective agent through induction of antiviral proteins, such as IFITM3, Interferon-stimulated gene 15, & Mx2.


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How Bacillus subtilis B10 increases the expression of Antiviral Protein IFITM3, Interferon-stimulated gene 15, & Mx2

Amount: $ 500#

# Research cooperation

For more details on payment, you may reach us at admin@genomediscovery.org


References: 

CitationBoominathan L, Combating infective agents with Probiotics:  Probiotics-based adjuvant therapy for viral and bacterial infections: Probiotic Bacillus subtilis B10 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene, 24/October/2018, 10.31 pm


Courtesy:
 When you cite drop us a line at info@genomediscovery.org,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.